Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 31, 2020
Event: Entry into a Material Definitive Agreement for a firm commitment underwritten offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key figures include:
- Shares Issued: 937,500 shares of common stock.
- Public Offering Price: $8.00 per share.
- Expected Net Proceeds: Approximately $7,050,000 (after underwriting discounts and commissions, before offering expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the execution of an underwriting agreement with Craig-Hallum Capital Group LLC. This represents a significant increase in the company's capital base pending the closing of the transaction.
Outlook, Risks, and Unusual Items
- Closing Date: The offering is scheduled to close on or about February 4, 2020, subject to customary closing conditions.
- Regulatory Basis: The offering is made pursuant to a previously effective Form S-3 registration statement (No. 333-234528).
- Agreement Terms: The Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 4, 2020).
- Confirm the actual net proceeds received after all offering expenses are deducted.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check subsequent filings for the impact of the new shares on diluted earnings per share and total share count.